Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Switching antiretroviral therapy to minimize metabolic complications.

Lake JE, Currier JS.

HIV Ther. 2010 Nov;4(6):693-711.

2.

Metabolic and body composition effects of newer antiretrovirals in HIV-infected patients.

Srinivasa S, Grinspoon SK.

Eur J Endocrinol. 2014 Apr 10;170(5):R185-202. doi: 10.1530/EJE-13-0967. Print 2014 May. Review.

3.

Diagnosis and management of common chronic metabolic complications in HIV-infected patients.

Bader MS, Kelly DV.

Postgrad Med. 2008 Nov;120(4):17-27. doi: 10.3810/pgm.2008.11.1930. Review.

PMID:
19020362
4.

Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.

Sturt AS, Dokubo EK, Sint TT.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD008440. doi: 10.1002/14651858.CD008440. Review.

PMID:
20238370
5.

Antiretroviral therapy with heart.

Randell P, Moyle G.

Am J Ther. 2009 Nov-Dec;16(6):579-84. doi: 10.1097/MJT.0b013e318192116f. Review.

PMID:
19940610
6.

Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus.

Grinspoon SK.

Am J Med. 2005 Apr;118 Suppl 2:23S-28S. Review.

PMID:
15903292
7.

HIV-associated lipodystrophy: pathogenesis, prognosis, treatment, and controversies.

Koutkia P, Grinspoon S.

Annu Rev Med. 2004;55:303-17. Review.

PMID:
14746523
8.

Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection.

Tebas P, Yarasheski K, Henry K, Claxton S, Kane E, Bordenave B, Klebert M, Powderly WG.

AIDS Res Hum Retroviruses. 2004 Jun;20(6):589-94.

PMID:
15242534
9.

Severe malnutrition and metabolic complications of HIV-infected children in the antiretroviral era: clinical care and management in resource-limited settings.

Musoke PM, Fergusson P.

Am J Clin Nutr. 2011 Dec;94(6):1716S-1720S. doi: 10.3945/ajcn.111.018374. Epub 2011 Nov 16. Review.

10.

Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel.

Schambelan M, Benson CA, Carr A, Currier JS, Dubé MP, Gerber JG, Grinspoon SK, Grunfeld C, Kotler DP, Mulligan K, Powderly WG, Saag MS; International AIDS Society-USA.

J Acquir Immune Defic Syndr. 2002 Nov 1;31(3):257-75. Review.

PMID:
12439201
11.

[Abnormal body fat distribution and type of antiretroviral therapy as predictors of cardiovascular disease risk in HIV-infected patients].

Ena J, Benito C, Llácer P, Pasquau F, Amador C.

Med Clin (Barc). 2004 May 22;122(19):721-6. Spanish.

PMID:
15171905
12.

Risk of premature atherosclerosis and ischemic heart disease associated with HIV infection and antiretroviral therapy.

Calza L, Manfredi R, Pocaterra D, Chiodo F.

J Infect. 2008 Jul;57(1):16-32. doi: 10.1016/j.jinf.2008.02.006. Epub 2008 Mar 21. Review.

PMID:
18358535
13.

Body-fat abnormalities in patients with HIV: progress and challenges.

Bedimo RJ.

J Int Assoc Physicians AIDS Care (Chic). 2008 Nov-Dec;7(6):292-305. doi: 10.1177/1545109708328931. Epub 2008 Dec 3. Review.

PMID:
19056708
14.

HIV lipodystrophy and its metabolic consequences: implications for clinical practice.

Wierzbicki AS, Purdon SD, Hardman TC, Kulasegaram R, Peters BS.

Curr Med Res Opin. 2008 Mar;24(3):609-24. doi: 10.1185/030079908X272742. Review.

PMID:
18208641
15.

Switching effective antiretroviral therapy: a review.

Drechsler H, Powderly WG.

Clin Infect Dis. 2002 Nov 15;35(10):1219-30. Epub 2002 Oct 21. Review.

PMID:
12410482
16.

Metabolic complications associated with antiretroviral therapy.

Jain RG, Furfine ES, Pedneault L, White AJ, Lenhard JM.

Antiviral Res. 2001 Sep;51(3):151-77. Review.

PMID:
11448728
17.

Cardiovascular risk factors in HIV-infected patients.

Carr A.

J Acquir Immune Defic Syndr. 2003 Sep;34 Suppl 1:S73-8. Review.

PMID:
14562861
18.

Dual therapy with darunavir/r plus etravirine is safe and effective as switching therapy in antiretroviral experienced HIV-patients. The BITER Study.

Portilla J, Arazo P, Crusells J, Pérez-Martínez L, Martínez-Madrid O, Boix V, Moreno J, Navarro V, Rubio T, Reus S, Galera C, Bernal E, Jover F, Amador C, Baño D, Merino E, Saiz-de-la-Hoya P.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19803. doi: 10.7448/IAS.17.4.19803. eCollection 2014.

19.

Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.

Calza L, Manfredi R, Chiodo F.

J Antimicrob Chemother. 2004 Jan;53(1):10-4. Epub 2003 Nov 25. Review.

PMID:
14645323
20.

Pharmacogenetics of the metabolic disturbances and atherosclerosis associated with antiretroviral therapy in HIV-infected patients.

Veloso S, Peraire J, Viladés C, López-Dupla M, Escoté X, Olona M, Garcia-Pardo G, Gómez-Bertomeu F, Soriano A, Sirvent JJ, Vidal F.

Curr Pharm Des. 2010 Oct;16(30):3379-89. Review.

PMID:
20687887

Supplemental Content

Support Center